{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:31:47Z","timestamp":1787236307120,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB027498-A1"],"award-info":[{"award-number":["R01EB027498-A1"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA238444-01A1"],"award-info":[{"award-number":["U01 CA238444-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amy Kronthal Fund for Liver Cancer"},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kao Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1245\/s10434-024-15724-9","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T09:11:33Z","timestamp":1721725893000},"page":"6551-6563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database"],"prefix":"10.1245","volume":"31","author":[{"given":"Lauren E.","family":"Schleimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Kalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Peter","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Drebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"6","key":"15724_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg. 2014;149(6):565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137.","journal-title":"JAMA Surg."},{"issue":"5","key":"15724_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2015-0446.","journal-title":"Oncologist."},{"issue":"5","key":"15724_CR3","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","volume":"28","author":"ZV Fong","year":"2021","unstructured":"Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann Surg Oncol. 2021;28(5):2660\u201374. https:\/\/doi.org\/10.1245\/s10434-021-09671-y.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"15724_CR4","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","volume":"274","author":"X-F Zhang","year":"2021","unstructured":"Zhang X-F, Xue F, Dong D-H, et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Ann Surg. 2021;274(6):e1187\u201395. https:\/\/doi.org\/10.1097\/SLA.0000000000003788.","journal-title":"Ann Surg."},{"key":"15724_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11463-x","author":"WJ Choi","year":"2022","unstructured":"Choi WJ, Williams PJ, Claasen MPAW, et al. Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11463-x.","journal-title":"Ann Surg Oncol."},{"issue":"27","key":"15724_CR6","doi-asserted-by":"publisher","first-page":"44521","DOI":"10.18632\/oncotarget.17815","volume":"8","author":"A Si","year":"2017","unstructured":"Si A, Li J, Xiang H, et al. Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(27):44521\u201332. https:\/\/doi.org\/10.18632\/oncotarget.17815.","journal-title":"Oncotarget."},{"issue":"1","key":"15724_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg."},{"issue":"7","key":"15724_CR8","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1245\/s10434-014-4223-3","volume":"22","author":"G Spolverato","year":"2015","unstructured":"Spolverato G, Kim Y, Alexandrescu S, et al. Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Ann Surg Oncol. 2015;22(7):2218\u201325. https:\/\/doi.org\/10.1245\/s10434-014-4223-3.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"15724_CR9","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s11605-019-04184-2","volume":"23","author":"S Buettner","year":"2019","unstructured":"Buettner S, Ten Cate DWG, Bagante F, et al. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2019;23(11):2239\u201346. https:\/\/doi.org\/10.1007\/s11605-019-04184-2.","journal-title":"J Gastrointest Surg."},{"issue":"23","key":"15724_CR10","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. J Clin Oncol. 2011;29(23):3140\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.35.6519.","journal-title":"J Clin Oncol."},{"issue":"1","key":"15724_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1245\/s10434-017-6110-1","volume":"25","author":"GP Wright","year":"2018","unstructured":"Wright GP, Perkins S, Jones H, et al. Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. Ann Surg Oncol. 2018;25(1):83\u201390. https:\/\/doi.org\/10.1245\/s10434-017-6110-1.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"15724_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0117","volume":"152","author":"M Raoof","year":"2017","unstructured":"Raoof M, Dumitra S, Ituarte PHG, et al. Development and validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma. JAMA Surg. 2017;152(5):e170117. https:\/\/doi.org\/10.1001\/jamasurg.2017.0117.","journal-title":"JAMA Surg."},{"issue":"9","key":"15724_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","volume":"31","author":"Y Wang","year":"2013","unstructured":"Wang Y, Li J, Xia Y, et al. Prognostic Nomogram for Intrahepatic Cholangiocarcinoma after Partial Hepatectomy. J Clin Oncol. 2013;31(9):1188\u201395. https:\/\/doi.org\/10.1200\/JCO.2012.41.5984.","journal-title":"J Clin Oncol."},{"issue":"2","key":"15724_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hpb.2018.08.006","volume":"21","author":"S Kizy","year":"2019","unstructured":"Kizy S, Altman AM, Marmor S, et al. Surgical Resection of Lymph node Positive Intrahepatic Cholangiocarcinoma may not Improve Survival. HPB (Oxford). 2019;21(2):235\u201341. https:\/\/doi.org\/10.1016\/j.hpb.2018.08.006.","journal-title":"HPB (Oxford)."},{"issue":"14","key":"15724_CR15","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-21-0412","volume":"27","author":"JS Jolissaint","year":"2021","unstructured":"Jolissaint JS, Soares KC, Seier KP, et al. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clin Cancer Res. 2021;27(14):4101\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0412.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"15724_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/hpb.12441","volume":"17","author":"SM Weber","year":"2015","unstructured":"Weber SM, Ribero D, O\u2019Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic Cholangiocarcinoma: Expert Consensus Statement. HPB (Oxford). 2015;17(8):669\u201380. https:\/\/doi.org\/10.1111\/hpb.12441.","journal-title":"HPB (Oxford)."},{"issue":"14","key":"15724_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med."},{"issue":"8","key":"15724_CR18","doi-asserted-by":"publisher","first-page":"VIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):VIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"10391","key":"15724_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (KEYNOTE-966): A Randomised, Double-blind, Placebo-controlled, Phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet."},{"issue":"16","key":"15724_CR20","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340. https:\/\/doi.org\/10.1200\/JCO.2011.40.5381.","journal-title":"J Clin Oncol."},{"issue":"3","key":"15724_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized Clinical Trial of Adjuvant Gemcitabine Chemotherapy Versus Observation in Resected Bile Duct Cancer. Br J Surg. 2018;105(3):192\u2013202. https:\/\/doi.org\/10.1002\/bjs.10776.","journal-title":"Br J Surg."},{"issue":"8","key":"15724_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019;37(8):658\u201367. https:\/\/doi.org\/10.1200\/JCO.18.00050.","journal-title":"J Clin Oncol."},{"key":"15724_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","volume":"164","author":"J Edeline","year":"2022","unstructured":"Edeline J, Hirano S, Bertaut A, et al. Individual Patient Data Meta-analysis of Adjuvant Gemcitabine-based Chemotherapy for Biliary tract Cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer. 2022;164:80\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.009.","journal-title":"Eur J Cancer."},{"issue":"5","key":"15724_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol."},{"issue":"18","key":"15724_CR25","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02568.","journal-title":"J Clin Oncol."},{"issue":"7","key":"15724_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/jamasurg.2022.1305","volume":"157","author":"CS Cho","year":"2022","unstructured":"Cho CS. Multifocal Intrahepatic Cholangiocarcinoma and Operative Management of Inoperable Disease. JAMA Surg. 2022;157(7):597. https:\/\/doi.org\/10.1001\/jamasurg.2022.1305.","journal-title":"JAMA Surg."},{"issue":"3","key":"15724_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.surg.2018.01.006","volume":"165","author":"QL Hu","year":"2019","unstructured":"Hu QL, Ellis RJ, Ko CY. Databases for surgical health services research: National cancer database. Surgery. 2019;165(3):499\u2013500. https:\/\/doi.org\/10.1016\/j.surg.2018.01.006.","journal-title":"Surgery."},{"key":"15724_CR28","unstructured":"American College of Surgeons. National Cancer Database (NCDB). Accessed December 8, 2023. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/"},{"issue":"12","key":"15724_CR29","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for Outcomes Research: A Review. JAMA Oncol. 2017;3(12):1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"key":"15724_CR30","volume-title":"AJCC Cancer Staging Manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti, editors. AJCC Cancer Staging Manual. UK: Springer-Verlag; 2010."},{"key":"15724_CR31","volume-title":"AJCC Cancer Staging Manual","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, et al editors. AJCC Cancer Staging Manual. UK: Springer; 2002."},{"key":"15724_CR32","volume-title":"AJCC Cancer Staging Manual","year":"2016","unstructured":"Amin MB, Edge SB, Greene FL, Compton CC, Gershenwald JE, editors. AJCC Cancer Staging Manual. UK: Springer; 2016."},{"key":"15724_CR33","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. 2021. Accessed 8 Dec 2023. https:\/\/www.r-project.org\/"},{"key":"15724_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/9781118715598.ch17","volume-title":"Guidelines for Reporting Health Research: A User\u2019s Manual","author":"M Cevallos","year":"2014","unstructured":"Cevallos M, Egger MS. STrengthening the Reporting of Observational studies in Epidemiology. In: D Moher, DG Altman, KF Schulz, I Simera, E Wager, editors. Guidelines for Reporting Health Research: A User\u2019s Manual. UK: Wiley; 2014. p. 169\u201379. https:\/\/doi.org\/10.1002\/9781118715598.ch17."},{"issue":"9","key":"15724_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"12","key":"15724_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02178.","journal-title":"J Clin Oncol."},{"key":"15724_CR37","unstructured":"National Comprehensive Cancer Network. Hepatobiliary Cancers Version 2.2022. National Comprehensive Cancer Network (NCCN); 2022."},{"issue":"7","key":"15724_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamasurg.2022.1298","volume":"157","author":"S Franssen","year":"2022","unstructured":"Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157(7):590\u20136. https:\/\/doi.org\/10.1001\/jamasurg.2022.1298.","journal-title":"JAMA Surg."},{"issue":"1","key":"15724_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol."},{"issue":"10","key":"15724_CR40","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(10):3729\u201337. https:\/\/doi.org\/10.1245\/s10434-020-08486-7.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"15724_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/hep.26958","volume":"60","author":"B Njei","year":"2014","unstructured":"Njei B. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma. Hepatology. 2014;60(3):1107\u20138. https:\/\/doi.org\/10.1002\/hep.26958.","journal-title":"Hepatology."},{"issue":"6","key":"15724_CR42","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.clinre.2020.03.024","volume":"44","author":"MM Gad","year":"2020","unstructured":"Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of cholangiocarcinoma; united states incidence and mortality trends. Clin Res Hepatol Gastroenterol. 2020;44(6):885\u201393. https:\/\/doi.org\/10.1016\/j.clinre.2020.03.024.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"8","key":"15724_CR43","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1245\/s10434-023-13567-4","volume":"30","author":"KE Rhodin","year":"2023","unstructured":"Rhodin KE, Liu A, Bartholomew A, et al. Trends in receipt of adjuvant chemotherapy and its impact on survival in resected biliary tract cancers. Ann Surg Oncol. 2023;30(8):4813\u201321. https:\/\/doi.org\/10.1245\/s10434-023-13567-4.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15724-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15724-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15724-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:28:41Z","timestamp":1726741721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15724-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["15724"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15724-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"LES, HLK, RJE, TPK, KCS, MID, and WRJ report no relevant conflicts of interest. VPB reports research funding from Genetech\/Roche and inventor on patent applications related to antigen cross-reactivity and neoantigen quality modelling. JD reports employment and leadership at American Regent (spouse), and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals and Ions pharmaceuticals. AC reports stock ownership in Haystack Oncology, consulting\/advisory roles at Bayer, Daiichi Sankyo\/Astra Zeneca, G1 Therapeutics, GlaxoSmithKline, Incyte, Janssen, Merck, and Seagen, research funding from GlaxoSmithKline, and Seagen. GKA reports consulting\/advisory roles at Agios, Genentech-Roche, Eisai, Servier, Arcus (spouse), Alligator (spouse), Agenus (spouse), BioNTech (spouse), Ipsen (spouse), Merck (spouse), Moma Therapeutics (spouse), Novartis (spouse), Syros (spouse), Leap Therapeutics (spouse), Astellas (spouse), BMS (spouse), Fibrogen (spouse), Revolution Medicine (spouse) and Merus (spouse). EMO reports consulting for Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine and Merus, Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) and Servier (spouse), and institutional research funding from Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, Digestive Care, and Break Through Cancer. JJH reports consulting\/advisory roles in Adaptimmune, Bristol-Myers Squibb, CytomX Therapeutics, Eisai, Elevar Therapeutics, Exelixis, Hepion Pharmaceuticals, Imvax, Lilly, Medivir, Merck, QED Therapeutics, and Zymeworks, and institutional research funding from Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Codiak Biosciences, Debiopharm Group, Genoscience Pharma, Incyte, Lilly, Loxo, Novartis, Pfizer, Polaris, Yiviva, and Zymeworks. MG reports travel, accommodations and expenses from Genentech. ACW reports consulting roles at Histosonic and institutional research funding from Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}